Skip to content

Chinese mRNA Vaccine Maker Abogen Seeks $300 Million in Funding

  • Abogen latest round led by SoftBank Vision Fund, Mirae Asset
  • Firm is working with Walvax on trials of mRNA booster shot
China Beijing SARS-CoV-2 Vaccines

Photographer: FeatureChina/Getty Images

Chinese mRNA vaccine developer Suzhou Abogen Biosciences Co. is raising about $300 million in fresh capital, people with knowledge of the matter said. 

The vaccine maker’s latest funding round is being led by SoftBank Vision Fund and joined by other investors including Mirae Asset Securities Co., said the people, who asked not to be identified as the information isn’t public. An announcement is expected as soon as next week, they said.